Sandoz has resolved its Hatch-Waxman patent-infringement dispute with AbbVie in the US over the originator’s Rinvoq (upadacitinib) extended-release tablets, declaring that its proposed abbreviated new drug application product infringes 23 patents shielding the mega-blockbuster JAK inhibitor.
According to a stipulation and order signed by Delaware district court judge Maryellen Noreika, “Sandoz admits that the asserted patents...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?